Therefore, the combination of Immune checkpoint inhibitors (ICIs) and EGFR mAbs may be a promising approach in the face of NSCLC patients with EGFR mutations that are high in PD-L1 expression (Yamada et al., 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.